Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $59.50 USD
Change Today -1.16 / -1.91%
Volume 1.5M
JUNO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

juno therapeutics inc (JUNO) Snapshot

Open
$61.38
Previous Close
$60.66
Day High
$61.38
Day Low
$57.00
52 Week High
03/31/15 - $64.55
52 Week Low
12/19/14 - $34.71
Market Cap
5.4B
Average Volume 10 Days
2.4M
EPS TTM
--
Shares Outstanding
90.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JUNO THERAPEUTICS INC (JUNO)

juno therapeutics inc (JUNO) Related Businessweek News

No Related Businessweek News Found

juno therapeutics inc (JUNO) Details

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has collaboration agreements with Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.

95 Employees
Last Reported Date: 03/19/15
Founded in 2013

juno therapeutics inc (JUNO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $229.5K
Compensation as of Fiscal Year 2013.

juno therapeutics inc (JUNO) Key Developments

Juno Therapeutics Inc.(NasdaqGS:JUNO) added to Russell 1000 Index

Juno Therapeutics, Inc has been added to Russell 1000 Index.

Juno Therapeutics Inc.(NasdaqGS:JUNO) added to Russell 3000 Index

Juno Therapeutics, Inc has been added to Russell 3000 Index.

Juno Therapeutics Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Juno Therapeutics Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $191.9 million compared to $51.6 million, net loss attributable to common stockholders of $191.9 million or $13.68 per basic and diluted share, compared with $51.8 million or $9.98 per basic and diluted share in 2013. Non-GAAP net earnings attributable to common stockholders was $22.7 million or $1.61 per basic and diluted share. For the year, the company reported loss from operations of $232.8 million compared to $51.7 million, net loss attributable to common stockholders of $310.9 million or $36.82 per basic and diluted share, compared with $51.8 million or $14.16 per basic and diluted share in 2013. Non-GAAP net earnings attributable to common stockholders was $61.2 million or $7.24 per basic and diluted share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUNO:US $59.50 USD -1.16

JUNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JUNO.
View Industry Companies
 

Industry Analysis

JUNO

Industry Average

Valuation JUNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUNO THERAPEUTICS INC, please visit www.junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.